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Conclusion: In patients not considered surgical candidates, endovas-
cular repair of aortic aneurysms involving the visceral segment is feasible with
low morbidity and mortality.
Summary: The authors sought to establish safety and efficacy of
endovascular repair of thoracoabdominal aortic aneurysms (TAAs). Patients
enrolled in this study were considered high-risk for conventional surgery.
Patients were enrolled between May 2004 and February 2006 in a program
to evaluate an endovascular grafting system. Each device was custom de-
signed for each patient according to information from high resolution CT
scanning. Data were collected regarding mortality, morbidity, procedure-
related deaths, and end points of endovascular repair. Patients were evalu-
ated at hospital discharge and at 1, 6, and 12 months postoperatively.
There were 73 patients enrolled. The TAAs were type I, II or III in 28
patients and type IV in 45. Mean aneurysm size was 7.1 cm (range, 4.5-11.3
cm). Regional anesthesia was used in 53%. There were no conversions to
open surgery and no known ruptures after treatment. Sixty-eight of 73
patients could be treated for a technical success rate of 93%. The 30-day
mortality was 5.5% (4 of 73). Eleven patients had major perioperative
complications, including paraplegia in 2.7%, new onset of dialysis in 1.4%,
prolonged ventilatory support in 6.8%, myocardial infarction in 5.5%, and
minor hemorrhagic stroke in 1.4%. Eighty-six percent of patients had no
major complications. Mean hospital stay was 8.6 days. No known instances
of stent migration or aneurysm growth have occurred in follow-up. Six
deaths have occurred during follow-up.
Comment: The authors are clearly technical wizards. Nevertheless, we
have to ask ourselves if a system that requires individual fabrication of grafts
will ever be suitable for generalized treatment of TAAs. The approach
outlined here demonstrates the feasibility of branch-graft technology for
treatment of TAAs and the potential for improved results over open repair.
The approach will have to be significantly modified in terms of decreasing
technical difficulty and improving graft availability to make this feasible
beyond a few selective centers.
Nitinol Stent Implantation Versus Percutaneous Transluminal Angio-
plasty in Superficial Femoral Artery Lesions up to 10 cm in Length: The
Femoral Artery Stenting Trial (FAST)
Krankenberg H, Schlüter M, Steinkamp HJ, et al. Circulation 2007;116:
285-92.
Conclusion: At 1 year, there is no difference in angiographic and
clinical outcomes in patients with short superficial femoral artery (SFA)
lesions treated with percutaneous balloon angioplasty (PTA) alone vs those
treated with primary nitinol stenting.
Summary: This is a randomized trial of SFA lesions with the maximum
length of 10 cm treated with primary angioplasty or primary implantation of
a Luminexx 3 stent (Bard Peripheral Vascular Inc, Tempe, Az). Primary
outcomes were restenosis and clinical outcome at 1 year.
There were 244 patients (168 men; 69  9 years) with a single SFA
lesion and chronic limb ischemia randomized to angioplasty alone or pri-
mary stenting. The mean length of lesions treated was 45 mm. Technical
success was defined as a residual stenosis of 50% for PTA and 30% for
stenting. Technical success was achieved in 79% of the 121 patients random-
ized to PTA alone and in 117 of the 123 patients (95%) randomized to
stenting. There were 13 PTA group patients (11%) who crossed over to
stenting. At 1 year, ultrasound-assessed stenosis was present in 39 of 101
PTA patients (38.6%) and 32 of 101 stent patients (32.7%), for an absolute
treatment difference of –6.9% (95% confidence interval [CI], –19.7% to
6.2%; P .377). Target lesion revascularization rates at 1 year for PTA alone
were 18.3% and 14.9% for primary stenting for an absolute treatment
difference of –3.3% (95% CI, –13.0% to 6.4%; P  .595). An assessment of
clinical difference, as defined by improvement of at least one category in the
Rutherford scale, found no significant difference between the two treatment
groups at 12 months.
Comment: The trial was designed to demonstrate a 20% absolute
reduction in ultrasound-assessed restenosis in the stented vs angioplasty-
only patients. A trial by Schillinger (N Eng JMed 2006;354:1879-88) using
a different manufacturer’s stent, allowing multiple stent implantations, and
treating lesions that averaged twice as long as those treated in this study, did
show benefit in reduction of restenosis in the stented vs nonstented patients.
A reasonable conclusion from these two studies is that angioplasty alone isless effective for longer SFA lesions and stenting adds little to treatment of
shorter SFA lesions.
Short-Term Pretreatment With Low-Dose Hydrogen Peroxide En-
hances the Efficacy of BoneMarrowCells for Therapeutic Angiogenesis
Kubo M, Li T, Suzuki R, et al. Am J Physiol Heart Circ Physiol 2007;292:
H2582-8.
Conclusion: Treatment of bone marrow cells (BMCs) with low-dose
hydrogen peroxide (H2O2) enhances their angiogenic potency.
Summary: There are currently a number of approaches and clinical
trials evaluating the possibility of inducing therapeutic angiogenesis as a
treatment for critical limb ischemia. Optimal delivery methods of angiogenic
stimuli and the best methods of stimulating angiogenesis are being actively
investigated. One possibility for stimulating angiogenesis is the use of
BMCs. Both preclinical and clinical trials suggest BMCs, including stem cells
and endothelial progenitor cells, can improve blood flow under ischemic
conditions.
Endothelial differentiation from implanted BMCs and secretion of
angiogenic cytokines, such as vascular endothelial growth factor (VEGF),
contribute to therapeutic angiogenesis (Nat Med 2001;7:430-6). Because
H2O2 increases VEGF expression, the authors tested the hypothesis that
pretreatment of BMCs with H2O2 may increase the efficacy of neovascular-
ization using BMCs. Pretreatment of BMCs was performed with H2O2 by
incubating mouse BMCs in 5M H2O2 for 30 minutes. Both BMCs
pretreated and BMCs untreated withH2O2were studied in vivo and in vitro.
Reverse transcriptase polymerase chain reaction analysis showed expression
of higher levels of Flk-1 messenger RNA in H2O2 pretreated BMCs (P 
.01). Production of VEGF and endothelial differentiation of bone marrow
cells after 1 and 7 days of culture was also enhanced with H2O2 (P  .05).
Bone marrow cells were also intramuscularly implanted into the isch-
emic hind limbs of mice. After 14 days of implantation, many H2O2-
pretreated BMCs were viable and demonstrated endothelial differentiation
and incorporation intomicrovessels. Survival and incorporation of untreated
BMCs was relatively poor. Blood flow and microvessel density in the
ischemic hind limbs was greater in mice that received BMCs pretreated with
H2O2 than in those implanted with untreated BMCs (P  .05).
Comment:Many approaches are being investigated for improving the
efficacy of angiogenesis associated with implantation of BMC’s. Approaches
using gene modification are potentially efficacious but difficult to imple-
ment. This study suggests there may be relatively simple methods for
improving the therapeutic potential of angiogenesis after BMC implanta-
tion.
Mortality Among Patients in VAHospitals in the First 2 Years Follow-
ing ACGME Resident Duty Hour Reform
Volpp KG, Rosen AK, Rosenbaum PR, et al. JAMA 2007;298:984-92.
Conclusion: New duty hour regulations implemented by the Accred-
itation Council for Graduate Medical Education (ACGME) were associated
with relative improvement in mortality in four common medical conditions
in teaching-intensive Veterans Administration (VA) hospitals. No mortality
changes were identified for surgical patients.
Summary:On July 1, 2003, the ACGME instituted limitations in duty
hours for United States resident physicians. The study sought to determine
whether there was an associated change in mortality among hospitalized
patients with duty hour reform. The authors determined whether there were
associated relative changes in mortality in hospitals of different teaching
intensity within the Department of Veterans Affairs health care system.
This was an observational study of 318,636 acute care patients admit-
ted to 131 VA hospitals from July 1, 2000, to June 30, 2005. Medical
conditions studied were acute myocardial infarction, congestive heart fail-
ure, gastrointestinal bleeding, and stroke. Patient admissions that were
determined by Diagnosis-Related Groups to be related to general, orthope-
dic, or vascular surgery were also studied. A logistic regression analysis
examined changes in mortality in more- or less-intensive teaching hospitals
before and after duty hour reform. Adjustments were made for time trends,
hospital sites, and patient comorbidities. The main outcome measure was
death 30 days of hospital admission.
Changes in mortality rates were not significant in the first year after
reform in either medical or surgical patients. In year 2 after reform, mortality
decreased significantly in more teaching-intensive hospitals for medical
patients only. When hospitals with a resident-to-bed ratio of 1 were com-
pared with hospitals with a resident-to-bed ratio of 0, mortality odds were
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